secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001193125-25-182222
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive and Genentech terminate cell therapy collaboration; $33.7M non-cash revenue in H2 2025
--------------------------------------------------------------------------------

- Strategic Collaboration and License Agreement with Genentech terminated Aug 13, 2025; effective Feb 9, 2026.
- Adaptive expects $33.7M non-cash revenue in H2 2025 from remaining amortization of cash consideration.
- Company released from exclusivity obligations in oncology cell therapies.
- Ongoing Immune Medicine programs: digital TCR-antigen models, T-cell depletion in autoimmunity, FY2025 cash burn target $25-30M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000119312525182222/0001193125-25-182222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000119312525182222/d59058d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-182222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer